Investor Presentation
65
Investor presentation
First six months of 2022
Novo NordiskⓇ
In STEP 1, 34.8% of patients treated with sema reached ≥20%
weight loss and reported improved quality of life versus placebo
Categorical weight loss
Sema 2.4 mg showed a statistically significant treatment
difference versus placebo in the IWQOL-Lite-CT PRO
Proportion of
patients
100%
92.4%
80%
60%
40%
33.1%
74.8%
Sema 2.4 mg Placebo
IQWOL-Lite-CT
Physical function
54.8%
34.8%
Physical
Psychological
20%
11.8%
5.0%
Total
2.0%
0%
≥5%
≥10%
≥15%
≥20%
Weight loss
Descriptive statistic only. Based on the on-treatment data, i.e. data for people that are on-treatment at week 68
Sema: semaglutide
ETD [95% CI]
9.43 [7.50 11.35] *
9.14 [7.31 10.96] *
10.50 [8.81 12.19] *
10.02 [8.42: 11.62] *
Favours placebo
Favours semaglutide
-202
468 10
12
14
*statistically significant; p-values other than physical function were not controlled for multiplicity
PRO: patient reported outcome; CI: confidence interval, ETD: estimated treatment difference, IWQOL-Lite-CT: Impact of Weight on
Quality of Life-lite;View entire presentation